Jump to main content
Jump to site search

Issue 5, 2016
Previous Article Next Article

Biological evaluation of quinoline derivatives as inhibitors of human dihydroorotate dehydrogenase

Author affiliations

Abstract

Human dihydroorotate dehydrogenase (hDHODH) is an enzyme that catalyzes the fourth step in de novo pyrimidine biosynthesis, and its inhibitors restrict the growth of rapidly proliferating cells. Therefore, hDHODH has been reported as an attractive target for the treatment of cancer and autoimmune diseases. In this study, several quinoline derivatives were identified as potent inhibitors against hDHODH, among which compound A9 was the most potent one with an IC50 value of 9.7 nM. We further verified by thermal shift assay (TSA), surface plasmon resonance (SPR) and X-ray crystallography that A9 could directly bind to the target hDHODH. The crystal structure of hDHODH in complex with compound A9 was refined to 1.90 Å and the binding mode of compound A9 was summarized. Moreover, structure–activity relationship (SAR) analysis of quinoline derivatives with hDHODH indicated that quinoline derivatives with a carboxyl group in R1, a bromine atom in R2 and a para-alkyl-substituted phenyl group in R5, were beneficial for potency against hDHODH, which plays an important role in inhibitor design and optimization.

Graphical abstract: Biological evaluation of quinoline derivatives as inhibitors of human dihydroorotate dehydrogenase

Back to tab navigation

Publication details

The article was received on 12 Jan 2016, accepted on 01 Feb 2016 and first published on 05 Feb 2016


Article type: Research Article
DOI: 10.1039/C6MD00024J
Med. Chem. Commun., 2016,7, 853-858

  •   Request permissions

    Biological evaluation of quinoline derivatives as inhibitors of human dihydroorotate dehydrogenase

    J. Wang, Y. Diao, J. Zhu, S. Li, Z. Zhao, H. Li and L. Zhu, Med. Chem. Commun., 2016, 7, 853
    DOI: 10.1039/C6MD00024J

Search articles by author

Spotlight

Advertisements